CORRECTING and REPLACING Rosetta Genomics to Present at the 17th Annual Rodman & Renshaw Global Investment Conference
September 08 2015 - 3:30PM
Business Wire
In first paragraph, second sentence of release dated September
4, 2015, date of overview and update should read September 9, 2015
(instead of September 10, 2015).
The corrected release reads:
ROSETTA GENOMICS TO PRESENT AT THE
17TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT
CONFERENCE
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces that
Company management will participate in the upcoming 17th Annual
Rodman & Renshaw Global Investment Conference being held from
September 8-10, 2015 at the St. Regis Hotel in New York City. Ken
Berlin, Rosetta’s President and Chief Executive Officer, will
present a corporate overview and update on September 9, 2015 at
5:05 p.m. Eastern time.
A live audio webcast of Mr. Berlin’s presentation will be
available in the investor section of Rosetta Genomics’ website,
http://www.rosettagenomics.com, where it will also be archived for
90 days.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Rosetta’s cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited
to statements relating to Rosetta Genomics having a
best-in-class FISH testing program, Rosetta Genomics’ testing
turnaround times, Rosetta Genomics enhancing oncologist’s treatment
options and Rosetta Genomics achieving New York State approval for
any or all of its tests, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
Annual Report on Form 20-F for the year ended December 31,
2014 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150904005478/en/
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestors:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024